Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy

PURPOSE: Dexamethasone, plus a 5-HT3 receptor antagonist and an NK-1 receptor antagonist are recommended for controlling the chemotherapy-induced nausea and vomiting (CINV) of highly emetogenic chemotherapy. Several days of dexamethasone are effective for CINV; however, dexamethasone also has side e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Support Care Cancer
Hauptverfasser: Kosaka, Yoshimasa, Tanino, Hirokazu, Sengoku, Norihiko, Minatani, Naoko, Kikuchi, Mariko, Nishimiya, Hiroshi, Waraya, Mina, Katoh, Hiroshi, Enomoto, Takumo, Sato, Takeo, Kuranami, Masaru, Watanabe, Masahiko
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Berlin Heidelberg 2015
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4729792/
https://ncbi.nlm.nih.gov/pubmed/26349772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-015-2905-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge